Physician profile
Umer Farooq
NPI 1295391142
$5,092.58
in general payments reported to CMS, 2019-2025
17 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.79 · 2023: $784 · 2024: $2,196 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991 · Travel and Lodging: $465 · Grant: $387 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,990.86 |
| Travel and Lodging | $464.83 |
| Grant | $387.10 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.35 | 2023-2025 | |
| Olympus Corporation of The Americas | $464.83 | 2025 | Single Use Electrosurgical Knife Kd-655, Olympus, Disposable Distal Attachment |
| Intercept Pharmaceuticals, INC. | $429.10 | 2023-2025 | Ocaliva |
| Cook Incorporated | $387.10 | 2025 | |
| Pfizer INC. | $345.89 | 2022-2025 | |
| Gilead Sciences, INC. | $342.13 | 2023-2025 | Livdelzi, Vemlidy |
| Janssen Biotech, INC. | $319.69 | 2024-2025 | Stelara, Tremfya |
| Ipsen Biopharmaceuticals, INC | $281.20 | 2024 | Bylvay, Iqirvo |
| Phathom Pharmaceuticals, INC. | $236.64 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.83 | 2023-2024 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $149.83 | 2023-2024 | Terlivaz |
| Olympus America INC. | $143.65 | 2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Genzyme Corporation | $125.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.01 | 2024 | |
| Aimmune Therapeutics, INC. | $116.33 | 2025 | Zenpep |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $99.75 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $25.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.